Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline-rich transmembrane protein 1 (PRRT1) is a membrane protein primarily expressed in the brain, associated with the regulation of AMPA-type glutamate receptors (AMPARs) at extrasynaptic sites. PRRT1 is a component of native AMPAR complexes and is required for maintaining a pool of extrasynaptic AMPARs, thereby playing a critical role in synaptic plasticity such as long-term potentiation and depression. Knockout of PRRT1 in animal models leads to altered surface expression and phosphorylation of AMPARs, as well as impaired synaptic plasticity. PRRT1 is a member of the SynDIG protein family (specifically SynDIG4) and is also classified within the larger Dispanin protein family. It is involved in protein-protein interactions, especially with AMPAR subunits GluA1-GluA4 and the phosphatase PP2B, influencing the trafficking and stabilization of AMPARs during neuronal activity and memory processes[1][3][4][7]. No direct evidence currently implicates PRRT1 as a validated therapeutic target or indicates drug interactions, biomarker roles, or therapeutic safety concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proline-rich transmembrane protein 1 (PRRT1).